PRINCETON, N.J. , May 11, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that Al Altomari , Chairman and Chief Executive Officer, will participate in a virtual fireside chat as part of the 2020 RBC Capital Markets Global Healthcare...
FDA Approved Twirla ® Expected to Reach Wholesalers in the Fourth Quarter of 2020 $93.9 Million in Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at 4:30 PM ET PRINCETON, N.J. , May 05, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
Live Conference Call and Webcast at 4:30 p.m. ET PRINCETON, N.J. , April 23, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced it will report first quarter 2020 financial results after the market close on Tuesday, May 5,...
PRINCETON, N.J. , April 22, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the company has nominated Sharon Barbari for election as a class III director to replace Abhijeet Lele , a member of the company’s board...
PRINCETON, N.J. , Feb. 25, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a forward-thinking women’s healthcare company, today announced that the Company will visit the Nasdaq MarketSite in Times Square on Wednesday, February 26, 2020 ....
PRINCETON, N.J. , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced the pricing of its underwritten public offering of 15 million shares of its common stock at a public offering price of $3.00 per share....
PRINCETON, N.J. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All shares being offered are to be sold by Agile Therapeutics. ...
Current Cash and Cash Equivalents Expected to Meet Projected Operating Requirements through End of 2020 Twirla ® , Company’s Lead Product Candidate, Receives FDA Approval Company Plans to Commence Distributing Product to Wholesalers in the Fourth Quarter of 2020 PRINCETON, N.J. , Feb....
Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S....
Funding to Support the Company’s Commercialization Plans for Twirla ® PRINCETON, N.J. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced that it has entered into a senior secured term loan credit facility with Perceptive...
